Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Patrycja Gazinska"'
Autor:
Leonora De Boo, Jelmar Quist, Mark Opdam, Katarzyna Jozwiak, Patrycja Gazinska, Dennis Peters, Hugo M. Horlings, Tessa Gerjanne Steenbruggen, Lars C. Steggink, Elisabeth De Vries, Gabe S. Sonke, Jourik A. Gietema, Andrew Tutt, Marleen Kok, Anita Grigoriadis, Sabine C. Linn
Publikováno v:
Journal of Clinical Oncology. 40:541-541
541 Background: The meiotic DNA break regulator HORMAD1 is aberrantly expressed in many cancers and is associated with increased genomic instability. The susceptibility of HORMAD1 expressing tumors to agents targeting DNA damage repair (DDR) pathways
Autor:
Jane Macaskill, Alastair M. Thompson, Gemma Earl, Duncan Wheatley, Matt Trau, Patrycja Gazinska, Hannah Butler, Shah-Jalal Sarker, Timothy R. Wilson, Charles Zammit, Peter Schmid, A Shia, Louise Lim, Mark R. Lackner, Arnie Purushotham, Darren Korbie, Natalie Woodman, Sarah E Pinder, Sirwan Hadad, Paul N. Mainwaring, Peter J. Parker, Jennifer Hu, Steven Gendreau, Mika K. Derynck, Nigel J Bundred, Robert G. Price
Publikováno v:
Journal of Clinical Oncology. 34:1987-1994
Purpose Preclinical data support a key role for the PI3K pathway in estrogen receptor–positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether
Autor:
Orsolya Sipos, Charles M. Perou, Sarah Kernaghan, Maggie C.U. Cheang, Anita Grigoriadis, Joel S. Parker, Richard D. Kennedy, Judith M Bliss, Sarah E Pinder, Holly Tovey, Patrycja Gazinska, Katherine A. Hoadley, Syed Haider, Lucy Kilburn, Andrew Tutt
Publikováno v:
Journal of Clinical Oncology. 38:1074-1074
1074 Background: In the Triple Negative Trial we observed no improved response rate (RR) to C over D in aTNBC [Tutt et al, Nat Med 2018], but we did in BRCA1/2 mutated (mut) patients (pts). We hypothesise tumors with other aberrant DNA damage respons
Autor:
Andrew Tutt, Lucy Kilburn, Mitch Dowsett, Ben P. Haynes, Sarah Kernaghan, Patrycja Gazinska, Holly Tovey, Cheryl Gillett, Sarah E Pinder, Judith M Bliss, Anita Grigoriadis, Paul Ellis, Mark Harries, Julie Owen, Maggie C.U. Cheang, Investigators
Publikováno v:
Journal of Clinical Oncology. 33:1019-1019
1019 Background: The majority of triple negative breast cancers are of basal-like subtype (BLBC). There is uncertainty about concordance of intrinsic subtypes and ROR scores by PAM50 between matche...